Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

Haruki Uojima; Shuzo Kobayashi; Hisashi Hidaka; Takeshi Kinbara; Tomoaki Fujikawa; Tsuyoshi Nakayama; Hiroki Yamanoue; Takayuki Kanemaru; Tohru Hashimoto; Ji Hyun Sung; Makoto Kako; Wasaburo Koizumi

2019, Número 1

Ann Hepatol 2019; 18 (1)

Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

Uojima H, Kobayashi S, Hidaka H, Kinbara T, Fujikawa T, Nakayama T, Yamanoue H, Kanemaru T, Hashimoto T, Sung JH, Kako M, Koizumi W

Texto completo

Cómo citar este artículo

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 109-115
Archivo PDF: 164.58 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1 Pinzone MR, Zanghì AM, Rapisarda L, D’Agata V, Benanti F, Spartà D, Nunnari G, et al. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. Eur Rev Med Pharmacol Sci 2014; 18: 11-5.
2 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015; 60: 573-81.
3 von Köckritz L, Dufour JF. Management of chronic hepatitis C in 2017. Hamostaseologie 2017; 37: 186-95.
4 Latt N, Alachkar N, Gurakar A. Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol 2012; 8: 434-45.
5 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015; 7: 51-70.
6 Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017; 11: 559-67.
7 Johnson SJ, Parisé H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir/paritaprevir/ ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis C virus infection. J Med Econ 2016; 19: 983-94.
8 Fabrizi F. Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrol 2012; 2013: 159760.
9 Alseiari M, Meyer KB, Wong JB. Evidence underlying KDIGO (Kidney Disease: Improving Global Outcomes) guideline recommendations: a systematic review. Am J Kidney Dis 2016; 67: 417-22.
10 Kumada H, Chayama K, Rodrigues L Jr., Suzuki F, Ikeda K, Toyoda H, Sato K, et al. Randomized phase 3 trial of ombitasvir/ paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62: 1037-46.
11 Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-74.
12 Alshogran OY, Nolin TD. Implications of Kidney Disease on Metabolic Reduction. Curr Drug Metab 2016; 17: 663-72.
13 Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD. Effect of experimental kidney disease on the functional expression of hepatic reductases. Drug Metab Dispos 2015; 43: 100-6.
14 Tani S, Asayama K, Oiwa K, Harasawa S, Okubo K, Takahashi A, Tanabe A, et al. The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. Hypertens Res 2017; 40: 892-8.
15 Sueta D, Tabata N, Hokimoto S. Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertens Res 2017; 40: 423-8.
16 Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108: 157-63.
17 Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016; 150: 1590-8.
18 Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, et al. Therapy with ombitasvir/ paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat 2017; 24: 464-71.
19 Morisawa N, Koshima Y, Kuriyama S, Matsuyama M, Hayashi N, Satoh JI, Amemiya M, et al. Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis. Nephrology (Carlton) 2017; 22: 562-5.
20 Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence 2014; 8: 763-73.